News Novartis drug effective in advanced MS Siponimod slowed disability progression in secondary progressive multiple sclerosis
Views & Analysis After 2015's ‘breakthrough’ year for pharma approvals, will ... Roche's MS drug is among major drugs still to come in 2016.
News Scangos to leave Biogen at a crossroads Company has grown, but direction towards next stage is unclear
News GSK pursues $10.6bn takeover of cancer biotech Nuvalent GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
